Sanare Lab Fenbendazole
Mounting research is showing that the drug fenbendazole, most typically used as a canine deworming drug in veterinary practice, has potent anti-cancer effects. In lab experiments, it has been shown to block sugar uptake in cancer cells, kill cancer cells and reduce tumour size. It can also overcome cancer drug resistance, making it a valuable addition to other treatment strategies.
Fenbendazole is a benzimidazole derivative that has been in use worldwide since 1974. It acts as a broad spectrum anthelmintic against many different parasites, including pinworms, roundworms, hookworms and tapeworms.
It is believed to work by binding to -tubulin in parasite cells, inhibiting their polymerization and causing cell cycle arrest, apoptosis and other forms of cell death. It also interferes with aerobic glycolysis in cancer cells, blocking them from utilizing glucose at a rate 200 times faster than normal cells. This is known as the Warburg effect, and can be seen on PET scans where cancer cells take up more radioactive glucose than healthy cells.
Fenbendazole has been found to be safe and well tolerated in humans when taken at the recommended dosage of 222 mg daily. People with severe liver or kidney failure may have lower medication excretion rates, and should be monitored for possible side-effects. The most common side effects of fenbendazole are nausea, vomiting and diarrhea. Some people may experience a mild herx reaction, in which case the dosage should be decreased to 500 mg per day for a few weeks before returning to the regular dose. sanare lab fenbendazole